Brea, California, September 21st, 2016 – PharMedQuest, an innovative provider of Medical and Pharmaceutical Management Services, recently commissioned a White Paper from Access Market Intelligence (AMI), an independent market research company, entitled: Bend the Curve: A New Era for the Management of Specialty Pharmaceuticals.
“We commissioned this white paper to uncover objective payor and plan sponsor concerns for unsustainable medical benefit specialty drug trends,” said Kirby Eng, Vice President of Business Development for PharMedQuest. “We trust the findings will help provide clarity on key barriers, what’s working and what’s not as well as key elements needed to overcome a clearly vexing problem,” he added.
Biologic, biotechnology-based, rare disease, or high-cost pharmaceuticals, collectively known as specialty drugs, can be covered under the pharmacy benefit, the medical benefit, or both, depending on the benefit design plan sponsors require of the third-party administrator (including
the pharmacy benefit manager – PBM; administrative service organization – ASO; or any administrator of a medical or pharmacy benefit).
With the exception of a few key therapy areas, traditional tools used to manage specialty drugs under the medical benefit, such as prior authorizations and medical benefit carve-outs (i.e., “white-bagging”), have yielded limited value to plan sponsors.
This thought leadership analysis, with insights from recognized industry experts, lays out the current landscape of specialty drugs billed under the Medical Benefit, why current methods aren’t working and provides insights into best practices through an innovative new approach, Medical Benefit Drug Management (MBM).
You can download the AMI White Paper here: http://www.pharmedquest.com/white-paper/.
PharMedQuest is a national leader in providing proven cost-effective solutions to some of the most challenging issues in healthcare. We are dedicated to providing transparent and innovative drug management solutions that optimize the clinical, operational and financial complexities of medical specialty drug management for cancer and other complex and rare diseases.
With over 20 years of Experience, PharMedQuest delivers Insight and Value to its Clients through its services, which include holistic Medical Benefit drug management, real-time access to integrated drug utilization and financial metrics and intelligence, comprehensive 340B management, and many other integrated Pharmacy and Medical solutions that go beyond traditional PBM, Specialty Pharmacy, or Utilization Management tools. For more information about PharMedQuest services, call (714) 364-4008 or visit www.PharMedQuest.com.